London · Delayed Price · Currency is GBP · Price in GBX Fevertree Drinks Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 4% in 2025, driven by U.S. expansion and product diversification, with strong cash generation and improved margins. The Molson Coors partnership and robust supply chain position support confidence in 2026 EBITDA growth despite ongoing geopolitical risks.
-
H1 FY25 saw robust financials, with 2% constant currency growth and strong U.S. momentum from the Molson Coors partnership. Product diversification, especially ginger beer, is driving growth, while the expanded share buyback reflects confidence in future cash flows.
-
A new long-term partnership with Molson Coors will see them manage U.S. sales, distribution, and production, enabling Fever-Tree to leverage Molson Coors' scale, reduce working capital, and focus on brand growth. Guaranteed royalties and a shareholding stake de-risk profits and support long-term expansion.
Fiscal Year 2024
-
Fever-Tree achieved 4% constant currency growth in 2024, with strong U.S. and Rest of World performance, margin recovery, and robust cash generation. The Molson Coors partnership is set to drive future growth, profitability, and shareholder returns.
-
Delivered strong H1 2024 results with 79% EBITDA growth and 520 bps gross margin improvement, driven by robust U.S. and Rest of World performance, portfolio diversification, and continued investment in innovation. Outlook remains positive with further margin recovery and growth expected.